Great West Life Assurance Co. Can Reduces Stock Holdings in Alder Biopharmaceuticals Inc (NASDAQ:ALDR)

Great West Life Assurance Co. Can reduced its stake in shares of Alder Biopharmaceuticals Inc (NASDAQ:ALDR) by 46.9% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 2,085 shares of the biopharmaceutical company’s stock after selling 1,845 shares during the quarter. Great West Life Assurance Co. Can’s holdings in Alder Biopharmaceuticals were worth $39,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in shares of Alder Biopharmaceuticals by 1.7% during the 2nd quarter. Vanguard Group Inc. now owns 6,661,135 shares of the biopharmaceutical company’s stock valued at $78,402,000 after buying an additional 111,886 shares during the period. Marshall Wace LLP raised its holdings in shares of Alder Biopharmaceuticals by 7,812.2% during the 2nd quarter. Marshall Wace LLP now owns 1,675,804 shares of the biopharmaceutical company’s stock valued at $19,724,000 after buying an additional 1,654,624 shares during the period. Artal Group S.A. raised its holdings in shares of Alder Biopharmaceuticals by 70.0% during the 2nd quarter. Artal Group S.A. now owns 850,000 shares of the biopharmaceutical company’s stock valued at $10,005,000 after buying an additional 350,000 shares during the period. Northern Trust Corp raised its holdings in shares of Alder Biopharmaceuticals by 4.2% during the 2nd quarter. Northern Trust Corp now owns 781,822 shares of the biopharmaceutical company’s stock valued at $9,203,000 after buying an additional 31,794 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Alder Biopharmaceuticals by 11.5% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 425,222 shares of the biopharmaceutical company’s stock valued at $5,005,000 after buying an additional 43,849 shares during the period.

ALDR stock opened at $18.88 on Friday. The company has a quick ratio of 8.94, a current ratio of 8.94 and a debt-to-equity ratio of 1.74. Alder Biopharmaceuticals Inc has a 52-week low of $8.39 and a 52-week high of $19.12. The stock’s 50 day moving average is $18.85 and its two-hundred day moving average is $12.97. The company has a market capitalization of $1.58 billion, a PE ratio of -3.88 and a beta of 2.64.

Alder Biopharmaceuticals (NASDAQ:ALDR) last posted its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($0.72) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.99) by $0.27. As a group, sell-side analysts anticipate that Alder Biopharmaceuticals Inc will post -3.92 EPS for the current year.

In other Alder Biopharmaceuticals news, Director Jeffrey T. L. Smith sold 32,728 shares of Alder Biopharmaceuticals stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $18.44, for a total transaction of $603,504.32. Following the sale, the director now directly owns 27,999 shares in the company, valued at approximately $516,301.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 15.40% of the stock is owned by insiders.

Several equities research analysts recently commented on the company. BidaskClub upgraded Alder Biopharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, September 18th. UBS Group upgraded Alder Biopharmaceuticals from a “sell” rating to a “neutral” rating and raised their target price for the company from $9.00 to $19.50 in a report on Tuesday, September 17th. ValuEngine downgraded Alder Biopharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Svb Leerink downgraded Alder Biopharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Monday, September 16th. Finally, BMO Capital Markets downgraded Alder Biopharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Monday, September 16th. One analyst has rated the stock with a sell rating, ten have issued a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $18.83.

About Alder Biopharmaceuticals

Alder BioPharmaceuticals, Inc operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine in the United States, Australia, and Ireland. The company's lead product candidate is eptinezumab, a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide, which is in the late-stage clinical development for the prevention of migraine.

Read More: Range Trading

Institutional Ownership by Quarter for Alder Biopharmaceuticals (NASDAQ:ALDR)

Receive News & Ratings for Alder Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.